Highlights and Quick Summary
- Total current liabilities for the quarter ending September 30, 2022 was $119 Million (a -15.6% decrease compared to previous quarter)
- Year-over-year quarterly Total current liabilities decreased by -11.85%
- Annual Total current liabilities for 2021 was $135 Million (a 41.21% increase from previous year)
- Annual Total current liabilities for 2020 was $95.6 Million (a 58.4% increase from previous year)
- Annual Total current liabilities for 2019 was $60.4 Million (a 85.36% increase from previous year)
Visit stockrow.com/BBIO
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Total current liabilities of BridgeBio Pharma, Inc.
Most recent Total current liabilitiesof BBIO including historical data for past 10 years.Interactive Chart of Total current liabilities of BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. Total current liabilities for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | $119.0 | $141.0 | $103.0 | – |
| 2021 | $135.0 | $96.0 | $131.91 | $94.73 | $135.07 |
| 2020 | $95.65 | $75.71 | $92.64 | $64.91 | $95.65 |
| 2019 | – | – | $60.39 | $39.86 | $60.39 |
| 2018 | – | – | – | $32.58 | $32.58 |
| 2017 | – | – | – | – | $9.0 |
Business Profile of BridgeBio Pharma, Inc.
Sector: Healthcare
Industry: Biotechnology